Bayer's shares rose 10.5% on the London Stock Exchange due to increased demand for new cancer and kidney drugs in Q1 2025. Despite a 7.4% decline in EBITDA to €4.1 billion, it exceeded market expectations. Sales fell slightly by 0.1% to €13.7 billion. CEO Bill Anderson expressed optimism about the pharmaceutical division's performance. Bayer's pharmaceutical sales grew 4.4%, driven by North American demand, while crop-science sales dropped 4.1%. The company is monitoring economic changes and facing litigation from its Monsanto acquisition. Teljes cikk (Euronews.com)